Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Prostate Cancer: Update Bulletin #2 [April 2018]

Product Code:
596200967
Publication Date:
April 2018
Format:
PDF
Price:
$1,095

Gain new key opinion leader (KOL) insights on the latest events happening in the prostate cancer space. Topics covered include expert opinions on the FDA approval of Johnson & Johnson’s (J&J’s) next-generation androgen receptor inhibitor Erleada (apalutamide) in patients with non-metastatic castration-resistant prostate cancer (CRPC), data published from the PROSPER study for Pfizer/Astellas’ Xtandi (enzalutamide) in the non-metastatic CRPC population and the expanded approval for J&J’s Zytiga (abiraterone acetate) by the FDA in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Finally, the experts also provide candid insights into their expectations for Pfizer’s PARP inhibitor talazoparib which has entered Phase III development (TALAPRO-2 study) in combination with physician's choice of either Xtandi or Zytiga in patients with metastatic CRPC.

Business Questions:

• What are the experts’ opinions on the FDA approval of J&J’s Erleada in patients with non-metastatic CRPC based on the novel endpoint of metastasis-free survival (MFS)? 
• How do KOLs contrast and compare the efficacy of Erleada and Pfizer/Astellas’ Xtandi in the non-metastatic CRPC setting?
• In terms of safety, how do KOLs view the data reported for Erleada in the SPARTAN study?
• Do the KOLs anticipate Erleada and Xtandi to compete head-to-head for market share in the non-metastatic CRPC setting? If so, what will influence their prescribing choices?
• How do the experts view the expanded approval for J&J’s Zytiga in patients with mHSPC? Will the drug gain significant uptake in this setting going forward?
• Will Xtandi be able to compete with Zytiga in the mHSPC setting? What data do KOLs expect from the recently completed ENZAMET/ARCHES studies investigating Xtandi?
• What are KOL expectations for Pfizer’s PARP inhibitor talazoparib in prostate cancer and how can it differentiate itself from the other two PARP inhibitors in Phase III development [AstraZeneca’s Lynparza (olaparib) and Clovis Oncology’s Rubraca (rucaparib)]?
• In terms of mechanism of action, efficacy and safety, how do the three PARP inhibitors compare so far?

• Do KOLs think Pfizer’s combination of talazoparib with anti-androgen drugs in the TALAPRO-2 study is a promising strategy?
• If approved in prostate cancer, how and when will the PARP inhibitors be used?

 




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved